Navigation Links
Radiation Cocktail May Reduce Risk of Damage To Other Organs In Breast Cancer

A new study to be reported August 1 at the annual meeting of the American Association of Physicists in Medicine in Orlando, contends that a specific mixture// of electron and x-ray beams that are targeted at certain areas may reduce the risk of collateral damage in breast cancer patients. Jinsheng Li, Ph.D. (Jinsheng.Li@fccc.edu) and Chang-Ming Ma, Ph.D. of Fox Chase Cancer Center in Philadelphia developed this specific mixture using a computer-based approach.

In treating shallow tumors such as those that occur in the breast, physicians have been turning to mixed-beam radiation therapy (MBRT), which employs separate beams of electrons and photons (x-rays). The two types of radiation complement one another, as electrons generally travel to shallow depths while the x-rays can penetrate to deeper parts of the tumor as needed.

However, each beam interacts in complex ways with its environment, making their exact path to the tumor region hard to predict. Nonetheless, physicists can calculate the probability for a given beam to follow a desired trajectory.

Therefore, Li and Ma use computers to simulate billions of trips of each beam to the unique landscape of each tumor. Gathering the statistics from these billions of trials, they determine the best beam properties and mixtures.

The computer simulations helped oncologists send accurately targeted doses for 78 breast cancer patients receiving "hypofractionated" treatments, in which the patients received fewer, but more potent, doses of radiation. The beams delivered all the radiation within a small margin of the tumor's edge, dramatically reducing radiation damage to surrounding healthy tissue. The researchers expect their approach to provide benefits for reducing collateral damage in the treatment of shallow tumors in the breast, chest wall, and head-and-neck region. Associated Meeting Papers:

TU-D-224A-6, "Advanced Mixed Beam Therapy Using MERT and IMRT," Tuesd
'"/>




Page: 1 2

Related medicine news :

1. Radiation before surgery cuts cancer recurrence
2. UV Radiation induces Melanoma
3. Radiation reduces cancer recurrence
4. Radiation before surgery cuts cancer reappearance
5. Radiation Not Needed for Childhood Cancers
6. Does Radiation Cause Lung Cancer?
7. Radiation for Bone Pain
8. Radiation for Bone Pain
9. Radiation after Breast Reconstruction
10. Radiation Exposure Found To Affect Intellect Later In Life
11. Radiation Therapy An Effective Solution For Recurrent Prostate Cancer
Post Your Comments:
Other Medicine News:Health News:Know the Warning Signs of Stroke 2Health News:Know the Warning Signs of Stroke 3Health News:Know the Warning Signs of Stroke 4Health News:Researchers find roadmap to next-generation cancer therapies 2Health News:Americans believe wounded Iraq war veterans are not receiving high quality medical care in US 2Health News:Americans believe wounded Iraq war veterans are not receiving high quality medical care in US 3Health News:Drowsy Drivers Make Holiday Weekend Among the Most Dangerous 2Health News:Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking 2Health News:Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking 3Health News:Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking 4
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 1Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 4